A.E. BOYD III, M.D.; Seymour Reichlin, M.D., PH.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: In our article on diagnosis and therapy of galactorrhea and amenorrhea syndromes (1) we pointed out the clinical experience with bromergocryptine therapy in pregnancy. We reported that five birth defects, two major and three minor, were observed in 78 infants born to women who had been treated at some period during early pregnancy in Europe. The denominator should have read 108 rather than 78. Recent information provided to us by the manufacturer (Sandoz Laboratories) summarized information on 448 pregnancies that resulted in 369 live births. Among this larger population 11 malformations were cited, of which two (the
BOYD A, Reichlin S. Correction: Bromergocryptine and Birth Defects. Ann Intern Med. 1978;88:581. doi: https://doi.org/10.7326/0003-4819-88-4-581_2
Download citation file:
Published: Ann Intern Med. 1978;88(4):581.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use